Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation

H. C. Schouten, James Olen Armitage, Lynell Warren Klassen, W. P. Vaughan, Philip Jay Bierman, D. Weisenburger, A. Kessinger

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.

Original languageEnglish (US)
Pages (from-to)119-121
Number of pages3
JournalBone marrow transplantation
Volume4
Issue number1
StatePublished - Jan 1 1989

Fingerprint

Autologous Transplantation
Homologous Transplantation
Bone Marrow Transplantation
Lymphoma
Bone Marrow
Non-Hodgkin's Lymphoma
Siblings
Transplants
Interstitial Lung Diseases
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation. / Schouten, H. C.; Armitage, James Olen; Klassen, Lynell Warren; Vaughan, W. P.; Bierman, Philip Jay; Weisenburger, D.; Kessinger, A.

In: Bone marrow transplantation, Vol. 4, No. 1, 01.01.1989, p. 119-121.

Research output: Contribution to journalArticle

@article{0ad2853a439b48b5a8f3a9de5f1b24cc,
title = "Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation",
abstract = "Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.",
author = "Schouten, {H. C.} and Armitage, {James Olen} and Klassen, {Lynell Warren} and Vaughan, {W. P.} and Bierman, {Philip Jay} and D. Weisenburger and A. Kessinger",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "119--121",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation

AU - Schouten, H. C.

AU - Armitage, James Olen

AU - Klassen, Lynell Warren

AU - Vaughan, W. P.

AU - Bierman, Philip Jay

AU - Weisenburger, D.

AU - Kessinger, A.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.

AB - Two patients who underwent autologous bone marrow transplantation for recurrent non-Hodgkin's lymphoma relapsed at 46 and 28 days after the transplant. Both patients had an HLA-identical sibling and were treated with high-dose chemotherapy and allogeneic marrow transplantation. One patient is now 24 months after the allogeneic transplant without evidence of disease. The second patient died on day 7 with interstitial pneumonia. We conclude that high-dose therapy and allogeneic bone marrow transplantation after failure of autologous transplantation for non-Hodgkin's lymphoma is feasible and should be considered in young patients with HLA-identical siblings.

UR - http://www.scopus.com/inward/record.url?scp=0024505146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024505146&partnerID=8YFLogxK

M3 - Article

C2 - 2466510

AN - SCOPUS:0024505146

VL - 4

SP - 119

EP - 121

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -